stockportfolio.pro
Cytek Biosciences, Inc. Gross Profit 2020–2025
Cytek Biosciences, Inc. (CTKB) annual gross profit by fiscal year, computed from SEC filings. Compound growth +15.1%/yr over 5 years.
| Fiscal year | Gross Profit | Gross margin | Change (YoY) |
|---|---|---|---|
| FY 2025 | $104.46M | 51.8% | -6.0% |
| FY 2024 | $111.11M | 55.4% | +1.5% |
| FY 2023 | $109.43M | 56.6% | +8.4% |
| FY 2022 | $100.97M | 61.6% | +27.6% |
| FY 2021 | $79.14M | 3628.8% | +53.1% |
| FY 2020 | $51.71M | 7283.1% | — |
Source: Cytek Biosciences, Inc. SEC filings — income statement (10-K). Refreshed nightly.
See the full picture for Cytek Biosciences, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCytek Biosciences, Inc. — frequently asked questions
What is Cytek Biosciences, Inc.'s gross profit?
Cytek Biosciences, Inc. (CTKB) reported gross profit of $104.46M for fiscal year 2025, per its SEC filings.
How has Cytek Biosciences, Inc.'s gross profit changed over time?
Between fiscal 2020 and 2025, CTKB's gross profit grew at roughly 15.1% per year (compound annual rate), from $51.71M to $104.46M.
Where does this data come from?
Figures are computed from Cytek Biosciences, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.